A couple of molecular-targeting medications, such as Lenvatinib, are available for the
treatment of hepatocellular carcinoma (HCC) in addition to Sorafenib in an advanced stage …

Hepatocellular carcinoma (HCC) is one of the deadliest cancers because of late symptom
manifestation leading to delayed diagnosis, which limits patients with HCC in terms of …

Objective A comprehensive understanding of anticancer immune responses is paramount
for the optimal application and development of cancer immunotherapies. We unravelled …

Immunotherapies targeting immune checkpoints are fast-developing therapeutic
approaches adopted for several tumor types that trigger unprecedented rates of durable …

Background & Aims TIGIT is a co-inhibitory receptor, and its suitability as a target for cancer
immunotherapy in HCC is unknown. PD1 blockade is clinically effective in about 20% of …

Simple Summary Hepatocellular carcinoma (HCC) represents one of the main indications
for liver transplantation. Over recent years, immune checkpoint inhibitor (ICI) therapy has …

Hepatocellular carcinoma (HCC) is a heterogeneous inflammation-driven malignancy,
which, despite significant advances in management, continues to portend a poor prognosis …

Background and Aims Targeting costimulatory receptors with agonistic antibodies is a
promising cancer immunotherapy option. We aimed to investigate costimulatory receptor …

The development of immunotherapy for solid tumours has boosted interest in the contexture
of tumour immune microenvironment (TIME). Several lines of evidence indicate that the …

Accumulating evidence supports the association of somatic mutations with tumor occurrence
and development. We aimed to identify somatic mutations with important implications in …